FDA Generic “Shared” Exclusivity Policy Needs Judicial Clarity, Troy Says

FDA's patent-based approach to awarding generic marketing exclusivity is the only remaining issue of legal uncertainty under the original Waxman/Hatch framework, former FDA Chief Counsel Dan Troy said